{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T20:06:32Z","timestamp":1777579592397,"version":"3.51.4"},"reference-count":28,"publisher":"SAGE Publications","issue":"3","license":[{"start":{"date-parts":[[2008,5,1]],"date-time":"2008-05-01T00:00:00Z","timestamp":1209600000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Journal of Ophthalmology"],"published-print":{"date-parts":[[2008,5]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>To investigate the incidence of latanoprost-related adverse events of the cornea, iris, and retina and the occurrence of hyperpigmentation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>An open-label safety surveillance study was conducted in 14 countries. Patients on intraocular pressure (IOP)-reducing therapy other than latanoprost were eligible if they required a change in therapy Patients were randomly assigned (2:1) to latanoprost administered once daily or to usual care (any other commercially available medication). Patients were examined at baseline and every 6 months for 5 years.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In all, 5854 patients were included (latanoprost, 3936; usual care, 1918). Of those initially randomized to latanoprost, 2707 (68.8%) completed the study, and 4638 (79.2%) patients received at least one dose of latanoprost. Five-year risks were \u22643.17% for new occurrences of corneal erosions, iritis\/uveitis, or macular edema in both randomization groups. Serious adverse drug reactions were reported in 17\/3936 (0.43%) latanoprost and 9\/1918 (0.47%) usual care patients. In all, 87.6% of patients ever treated with latanoprost had no increased iris pigmentation; no serious adverse drug reactions were reported in patients with increased iris pigmentation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This 5-year study suggests that latanoprost as prescribed in 14 countries is a safe long-term treatment for patients with glaucoma and ocular hypertension.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/112067210801800315","type":"journal-article","created":{"date-parts":[[2018,1,19]],"date-time":"2018-01-19T00:51:56Z","timestamp":1516323116000},"page":"408-416","source":"Crossref","is-referenced-by-count":28,"title":["A 5-year, Randomized, Open-Label Safety Study of Latanoprost and Usual Care in Patients with Open-Angle Glaucoma or Ocular Hypertension"],"prefix":"10.1177","volume":"18","author":[{"given":"I.","family":"Goldberg","sequence":"first","affiliation":[{"name":"Eye Associates, Glaucoma Services, Sydney Eye Hospital, University of Sydney - Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"X.-Y.","family":"Li","sequence":"additional","affiliation":[{"name":"Allergan, Inc., Irvine, California"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Selaru","sequence":"additional","affiliation":[{"name":"Ophthalmology, Pfizer Inc."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Paggiarino","sequence":"additional","affiliation":[{"name":"Clinical Biostatistics, Pfizer Inc., San Diego, California - USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2018,1,18]]},"reference":[{"key":"bibr1-112067210801800315","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0420.2000.078001071.x"},{"key":"bibr2-112067210801800315","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-002-0469-8"},{"key":"bibr3-112067210801800315","doi-asserted-by":"publisher","DOI":"10.1016\/S0161-6420(98)91372-0"},{"key":"bibr4-112067210801800315","doi-asserted-by":"publisher","DOI":"10.1177\/112067210501500128"},{"key":"bibr5-112067210801800315","first-page":"679","volume":"116","author":"Avakian A.","year":"1998","journal-title":"Arch Ophthalmol"},{"key":"bibr6-112067210801800315","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9394(98)00127-5"},{"key":"bibr7-112067210801800315","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9394(98)00082-8"},{"key":"bibr8-112067210801800315","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9394(98)00071-3"},{"key":"bibr9-112067210801800315","first-page":"680","volume":"116","author":"Heier J.S.","year":"1998","journal-title":"Arch Ophthalmol"},{"key":"bibr10-112067210801800315","doi-asserted-by":"publisher","DOI":"10.1177\/112067210301300219"},{"key":"bibr11-112067210801800315","doi-asserted-by":"publisher","DOI":"10.1016\/S0161-6420(99)00528-X"},{"key":"bibr12-112067210801800315","doi-asserted-by":"publisher","DOI":"10.1016\/S0161-6420(98)91105-8"},{"key":"bibr13-112067210801800315","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.82.7.841c"},{"key":"bibr14-112067210801800315","doi-asserted-by":"publisher","DOI":"10.1016\/S0161-6420(98)92977-3"},{"key":"bibr15-112067210801800315","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-5155(02)00622-6"},{"key":"bibr16-112067210801800315","doi-asserted-by":"publisher","DOI":"10.1016\/S0161-6420(95)30798-1"},{"key":"bibr17-112067210801800315","doi-asserted-by":"publisher","DOI":"10.1016\/S0161-6420(96)30750-1"},{"key":"bibr18-112067210801800315","doi-asserted-by":"publisher","DOI":"10.1016\/S0039-6257(02)00328-4"},{"key":"bibr19-112067210801800315","doi-asserted-by":"publisher","DOI":"10.1016\/S0039-6257(02)00302-8"},{"key":"bibr20-112067210801800315","doi-asserted-by":"publisher","DOI":"10.1016\/S0161-6420(96)30749-5"},{"key":"bibr21-112067210801800315","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.1996.01100140137004"},{"key":"bibr22-112067210801800315","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.85.10.1163"},{"key":"bibr23-112067210801800315","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.122.7.957"},{"key":"bibr24-112067210801800315","doi-asserted-by":"publisher","DOI":"10.1016\/0007-0971(87)90104-5"},{"key":"bibr25-112067210801800315","doi-asserted-by":"publisher","DOI":"10.1016\/S0039-6257(97)80017-3"},{"key":"bibr26-112067210801800315","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.117.10.1305"},{"key":"bibr27-112067210801800315","doi-asserted-by":"publisher","DOI":"10.1016\/S0039-6257(02)00328-4"},{"key":"bibr28-112067210801800315","doi-asserted-by":"publisher","DOI":"10.1016\/S0039-6257(02)00302-8"}],"container-title":["European Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/112067210801800315","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/112067210801800315","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T19:37:57Z","timestamp":1777405077000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/112067210801800315"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,5]]},"references-count":28,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2008,5]]}},"alternative-id":["10.1177\/112067210801800315"],"URL":"https:\/\/doi.org\/10.1177\/112067210801800315","relation":{},"ISSN":["1120-6721","1724-6016"],"issn-type":[{"value":"1120-6721","type":"print"},{"value":"1724-6016","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,5]]}}}